Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Hepatitis B Vaccine and the Risk of CNS Inflammatory Demyelination in Childhood
Neurol 72:873-880,870, Mikaeloff,Y.,et al, 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006